New
HealthMore in Health→
Personalized RNA therapy shows early gains in rare SCN2A epilepsy
Key Takeaways
- Nature Medicine published two individualized SCN2A antisense case studies on July 21, 2026.
- Researchers designed allele-selective ASOs to suppress mutant SCN2A transcripts while preserving the healthy copy.
- The two patients showed seizure reductions, lower use of other medications, and developmental improvement.
- Authors say longer-term follow-up is required to confirm disease-modifying benefit and scalability.
DE
DT Editorial Team··via nature.com